ERK pathway inhibitors: how low should we go?

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Resistance to RAF inhibitors is a significant clinical challenge.
• Reactivation of extracellular signal-regulated kinase (ERK) signaling is a common mechanism of resistance.
• Current RAF inhibitors are ineffective in certain tumor types with ERK dysregulation.

Purpose of the Study:

• To evaluate the efficacy of SCH772984, a selective ERK1 and ERK2 inhibitor.
• To assess SCH772984's potential in overcoming RAF inhibitor resistance.
• To explore SCH772984's utility in tumors with ERK dysregulation beyond BRAF mutations.

Main Methods:

• Utilized BRAF-mutant cancer models exhibiting ERK reactivation.
• Administered SCH772984, an ATP-competitive ERK inhibitor.
• Investigated efficacy in models with ERK dysregulation due to mutant RAS, NF1, or activated receptor tyrosine kinases.

Main Results:

• SCH772984 demonstrated effectiveness in BRAF-mutant models with ERK reactivation.
• The study suggests SCH772984's potential against tumors driven by various ERK pathway alterations.
• Identified potential therapeutic applications for SCH772984 where current RAF inhibitors fail.

Conclusions:

• SCH772984 is an effective inhibitor of ERK1 and ERK2.
• SCH772984 can overcome resistance to RAF inhibitors caused by ERK reactivation.
• SCH772984 represents a promising therapeutic strategy for a broader range of cancers with ERK pathway dysregulation.